Thermo Fisher Scientific Inc. $TMO Shares Acquired by Raiffeisen Bank International AG

Raiffeisen Bank International AG boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,757 shares of the medical research company’s stock after buying an additional 1,871 shares during the quarter. Thermo Fisher Scientific accounts for approximately 0.8% of Raiffeisen Bank International AG’s holdings, making the stock its 22nd biggest holding. Raiffeisen Bank International AG’s holdings in Thermo Fisher Scientific were worth $70,154,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TMO. J. Stern & Co. LLP boosted its holdings in Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $15,501,867,000. State Street Corp boosted its stake in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after buying an additional 229,630 shares during the last quarter. Corient Private Wealth LP acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $382,547,000. Finally, Capital World Investors increased its stake in shares of Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after buying an additional 718,669 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph Holmes sold 420 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Shafer sold 25,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $618.91 on Friday. The company has a market cap of $228.84 billion, a P/E ratio of 33.29, a PEG ratio of 2.54 and a beta of 0.85. The business has a 50 day moving average of $568.92 and a two-hundred day moving average of $514.41. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the firm earned $4.28 EPS. The business’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. CLSA assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday. They set an “outperform” rating and a C$748.00 price objective on the stock. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. Finally, Piper Sandler lifted their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.